JP2016539935A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539935A5
JP2016539935A5 JP2016529439A JP2016529439A JP2016539935A5 JP 2016539935 A5 JP2016539935 A5 JP 2016539935A5 JP 2016529439 A JP2016529439 A JP 2016529439A JP 2016529439 A JP2016529439 A JP 2016529439A JP 2016539935 A5 JP2016539935 A5 JP 2016539935A5
Authority
JP
Japan
Prior art keywords
agent
agent according
animal
anaplerotic
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016529439A
Other languages
English (en)
Japanese (ja)
Other versions
JP6588903B2 (ja
JP2016539935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065670 external-priority patent/WO2015073803A1/en
Publication of JP2016539935A publication Critical patent/JP2016539935A/ja
Publication of JP2016539935A5 publication Critical patent/JP2016539935A5/ja
Application granted granted Critical
Publication of JP6588903B2 publication Critical patent/JP6588903B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016529439A 2013-11-14 2014-11-14 神経変性障害、ならびにその治療及び診断法 Expired - Fee Related JP6588903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904365P 2013-11-14 2013-11-14
US61/904,365 2013-11-14
PCT/US2014/065670 WO2015073803A1 (en) 2013-11-14 2014-11-14 Neurodegenerative disorders and methods of treatment and diagnosis thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019167372A Division JP2020063233A (ja) 2013-11-14 2019-09-13 神経変性障害、ならびにその治療及び診断法

Publications (3)

Publication Number Publication Date
JP2016539935A JP2016539935A (ja) 2016-12-22
JP2016539935A5 true JP2016539935A5 (https=) 2017-12-21
JP6588903B2 JP6588903B2 (ja) 2019-10-09

Family

ID=53058060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016529439A Expired - Fee Related JP6588903B2 (ja) 2013-11-14 2014-11-14 神経変性障害、ならびにその治療及び診断法
JP2019167372A Pending JP2020063233A (ja) 2013-11-14 2019-09-13 神経変性障害、ならびにその治療及び診断法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019167372A Pending JP2020063233A (ja) 2013-11-14 2019-09-13 神経変性障害、ならびにその治療及び診断法

Country Status (7)

Country Link
US (3) US9833430B2 (https=)
EP (2) EP3068492B1 (https=)
JP (2) JP6588903B2 (https=)
AU (1) AU2014348457B2 (https=)
CA (1) CA2929601A1 (https=)
ES (1) ES2774321T3 (https=)
WO (1) WO2015073803A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
ES2728727T3 (es) 2012-12-13 2019-10-28 Baylor Res Institute At Dallas Triheptanoína para el tratamiento de la deficiencia del transportador de glucosa 1
US9833430B2 (en) 2013-11-14 2017-12-05 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
WO2017208217A2 (en) * 2016-06-01 2017-12-07 Aspi Ip Holder Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
US11406616B2 (en) 2016-06-08 2022-08-09 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113917034A (zh) * 2021-10-19 2022-01-11 北京豪思生物科技有限公司 用于评估阿尔茨海默症的生物标记组合及其应用和试剂盒
WO2024155950A2 (en) * 2023-01-20 2024-07-25 Keto Innovations, Llc C5 ketone compositions and related methods for therapeutic and performance supplementation
WO2025184834A1 (zh) * 2024-03-06 2025-09-12 中国科学院昆明动物研究所 一种庚酸酯化合物及其用于制备预防和/或治疗神经退行性疾病的药物或功能食品中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025649A (en) 1974-08-19 1977-05-24 Labaz Acetic acid derivatives having pharmacological activity and compositions containing the same
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
GB2104079B (en) 1981-08-14 1985-08-21 London Polytech New aminoacid isomers, their production and their medicinal use
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6740679B1 (en) 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
EP1150579B1 (en) 1999-02-05 2005-08-31 Baylor Research Institute Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven carbon fatty acid
CA2389623A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
WO2007115282A2 (en) 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001257451A1 (en) 2000-05-01 2001-11-12 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US20060189545A1 (en) 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
US8399515B2 (en) 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US8106093B2 (en) 2004-07-02 2012-01-31 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
WO2008039855A2 (en) 2006-09-26 2008-04-03 Baylor Research Institute Nutrient sensor
EP1929995A1 (en) * 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
CA2853992C (en) 2007-07-31 2020-06-23 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
WO2009124250A1 (en) 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for detecting tricarboxylic acid (tca) metabolic flux
CA2785714C (en) 2009-12-30 2016-01-26 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
CN103079555A (zh) * 2010-06-14 2013-05-01 贝勒研究院 用于成人葡萄糖多聚体病(apbd)治疗的三庚酸甘油酯膳食
JP6054301B2 (ja) 2010-12-23 2017-01-11 アマゼンティス エスアーAmazentis Sa ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
EP2599482A1 (en) 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
ES2728727T3 (es) 2012-12-13 2019-10-28 Baylor Res Institute At Dallas Triheptanoína para el tratamiento de la deficiencia del transportador de glucosa 1
US9833430B2 (en) 2013-11-14 2017-12-05 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof

Similar Documents

Publication Publication Date Title
JP2016539935A5 (https=)
JP2016503793A5 (https=)
JP2011527299A5 (https=)
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
EP2660241A3 (en) C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
JP2012097105A5 (https=)
EP2552203A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2016511753A5 (https=)
IL221764A (en) Use of bile acid sulfate to make pharmaceutical preparations for the treatment of fxr-related diseases
EP2120566A4 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
JP2018517666A5 (https=)
JP2011518833A5 (https=)
MY189770A (en) Biaryl derivative as gpr120 agonists
HRP20210999T1 (hr) Derivati tirozina i pripravci koji ih sadrže
JP2013515006A5 (https=)
JP2011046708A5 (https=)
JP2012520888A5 (https=)
EP2107870A4 (en) IMPROVED KLISTIER WITH REDUCED REIZEFFECT FOR THE TREATMENT OF INFLAMMABLE DARMER DISEASES
JP2018537513A5 (https=)
JP2017505809A5 (https=)
JP2016501249A5 (https=)
JP2014210824A5 (https=)
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
JP2013523623A5 (https=)